(44.200.74.241)
Users online: 4183    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 7
First page : ( 3472) Last page : ( 3479)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00616.2

A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 Inhibitors by HPLC in Its API and Dosage Form

Munde Manojkumar K.1,2,*, Kulkarni Nilesh S.2, Rukhe Nikita B.2, Sen Dhanya B.1

1Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat, India

2PES Modern College of Pharmacy (for Ladies), Moshi, Pune-412105, Maharashtra, India. Affiliated to Savitribai Phule Pune University, Pune

*Corresponding Author E-mail: manojpcist@gmail.com

Online published on 10 August, 2020.

Abstract

SGLT-2 is the newly developed class of antidiabetic medicine also called as gliflozins. Empagliflozin, dapagliflozin and canagliflozin are the SGLT-2 class inhibitors for the treatment of type II diabetes mellitus. SGLT-2 inhibitors shows the 82% of plasma protein binding, 36.8% of partitioning of red blood cells, 78% of bioavailability, 5.6 to 13.1 hrs half life in oral route of administration. In this review we complied analytical methods for the development and determination of the SGLT-2 inhibitors. Table no. 1, 2, 3 shows the analytical method development and validation of empagliflozin dapagliflozin and canagliflozin alone and with its combination by the HPLC method respectively also table no. 4 shows the various formulations available in SGLT-2 Inhibitors.

Top

Keywords

Empagliflozin, dapagliflozin, canagliflozin, pharmacokinetic parameters, pharmacodynamic parameters, HPLC method.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
556,698,931 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.